Synthetic peptide that moves stem cells from the bone marrow into the blood so they can be collected before an autotransplant in patients with multiple myeloma.
Regulatory status
Approved (FDA / EMA)
Family
CXCR4 receptor antagonist (stem cell mobilizer)
Scientific evidence
High
Number of findings
1
Where it acts
Immunity and defense · Heart and blood
Also known as
motixafortide, Aphexda, BL-8040, BKT140
Regulatory status
FDA (US): Approved (2023, Aphexda), together with filgrastim, to mobilize hematopoietic stem cells for autologous transplant in multiple myeloma
EMA (EU): No application / not approved
Dose
1.25 mg/kg subcutaneously, one dose after 4 days of filgrastim and 10–12 h before the first apheresis; it may be repeated before a third apheresis (FDA 2023, GENESIS trial).
Safety
Very common injection-site reactions (pain, redness, itching), allergic or anaphylactic-type reactions (premedication is recommended), and possible mobilization of tumor cells. May harm the fetus: contraception is recommended. Hospital use only and under medical supervision.
Differences between women and men
In the GENESIS trial (35% women), the FDA states that it worked similarly in men and women and that adverse effects were also similar.
Effect by goal · level of evidence
Stem cell collection in multiple myeloma
improvesHighRCT (AA)in people
92% vs 26%
In 122 patients, 92.5% with motixafortide + G-CSF reached the CD34+ cell target in a maximum of two apheresis sessions, versus 26.2% with placebo + G-CSF. In a single apheresis, 88.8% versus 9.5%.
It blocks the CXCR4 receptor, which works as an anchor that holds stem cells in the bone marrow. Once that anchor is released, the cells pass into the blood in large numbers and are collected by apheresis. It is combined with G-CSF (filgrastim).
What the evidence says
In people
Stem cell collection in multiple myeloma. In 122 patients, 92.5% with motixafortide + G-CSF reached the CD34+ cell target in at most two apheresis sessions, versus 26.2% with placebo + G-CSF. In a single apheresis, 88.8% versus 9.5%. PubMed 37069359